The second Phase III clinical study was approved by US Food and Drug Administration (FDA) on 3rd March 2018 for the new drug ON101 which is indicated for the chronic diabetic foot ulcer and developed by Oneness Biotech. ON101 is the first new drug in Taiwan with two Phase III clinical studies approved by...Read More